Perspective Therapeutics, Inc.
Ticker: 728387
values in millions
Revenue & Profit Trend
in millionsRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q3 FY2023 | Q2 FY2023 | Q1 FY2023 | Q3 FY2022 | Q1 FY2022 | Q4 FY2021 | Q3 FY2021 |
|---|---|---|---|---|---|---|---|
| INCOME | |||||||
| Revenue | 2.19+4.8% | 2.09+1.5% | 2.06+19.8% | 1.72-40.9% | 2.91+3.2% | 2.82+10.2% | 2.56 |
| Total Income | 2.19+4.8% | 2.09+1.5% | 2.06+19.8% | 1.72-40.9% | 2.91+3.2% | 2.82+10.2% | 2.56 |
| EXPENSES | |||||||
| Expenditure | 12.72-5.5% | 13.46+1.3% | 13.29+124.1% | 5.93+38.2% | 4.29-3.6% | 4.45-8.1% | 4.84 |
| Tax | 0.00 | 0.00+100.0% | -10.50 | — | — | — | — |
| PROFIT | |||||||
| PBT | -10.36+6.8% | -11.11-2.2% | -10.87 | — | — | — | — |
| Net Profit | -10.36+6.8% | -11.11-2902.7% | -0.37+90.9% | -4.07-201.5% | -1.35+15.6% | -1.60+28.6% | -2.24 |
| KEY METRICS | |||||||
| OPM % | -100.00% | -100.00% | -100.00% | -100.00%-52.71pp | -47.28%+10.78pp | -58.06%+30.63pp | -88.69% |
| NPM % | -100.00% | -100.00%-82.01pp | -17.98%+82.01pp | -100.00%-53.71pp | -46.29%+10.67pp | -56.96%+30.52pp | -87.48% |
| EPS | -0.04+0.0% | -0.04 | 0.00+100.0% | -0.03-200.0% | -0.01 | — | — |
Corporate Events
Board MeetingCATX
20268Jul
Board Meeting
Paul Lyne appointed Chief Science Officer; Michael K. Schult…
SEC Filing ↗ Board MeetingCATX
202627May
Board Meeting
2026 Annual Meeting of Stockholders to vote on the election …
SEC Filing ↗